Measurement of disease severity in cutaneous autoimmune diseases

F1000Prime Reports

Volumn 5, Issue , 2013, Pages

  Anyanwu, Cynthia ^a,b   Langenhan, Jamie ^a,b   Werth, Victoria P ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; BIOLOGICAL MARKER; INTERFERON REGULATORY FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ALOPECIA AREATA; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COLORIMETRY; CONSENSUS; CYTOKINE RELEASE; DERMATOMYOSITIS; DIFFUSE REFLECTANCE SPECTROSCOPY; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; ERYTHEMA; HISTOPATHOLOGY; HUMAN; MEDICAL SPECIALIST; OUTCOME ASSESSMENT; PATIENT CARE; PEMPHIGUS; POSTINFLAMMATORY HYPERPIGMENTATION; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS DISABILITY INDEX; QUALITY OF LIFE; RATING SCALE; SKIN; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSLATIONAL RESEARCH; VITILIGO;

EID: 84880048882     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P5-19     Document Type: Article

References (54)

1. Albrecht J, Werth VP: Clinical outcome measures for cutaneous lupus erythematosus. Lupus 2010, 19:1137-43.
2. Eleftheriadou V, Thomas KS, Whitton ME, Batchelor JM, Ravenscroft JC: Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials. Br J Dermatol 2012, 167:804-14.
3. Vrijman C, Homan ML, Limpens J, Van Der Veen W, Wolkerstorfer A, Terwee CB, Spuls PI: Measurement Properties of Outcome Measures for Vitiligo: A Systematic Review. Arch Dermatol 2012, 1-8.
4. Kuhn A, Rondinone R, Doria A, Shoenfeld Y: 1st International Conference on Cutaneous Lupus Erythematosus Düsseldorf, Germany, September 1-5, 2004. Autoimmun Rev 2005, 4:66-78. (Pubitemid 40126375)
5. Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, Bystryn J, Cianchini G, Diaz L, Fivenson D, Hall R, Harman KE, Hashimoto T, Hertl M, Hunzelmann N, Iranzo P, Joly P, Jonkman MF, Kitajima Y, Korman NJ, Martin LK, Mimouni D, Pandya AG, Payne AS, Rubenstein D, Shimizu H, Sinha AA, Sirois D, Zillikens D, Werth VP: Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008, 58:1043-6.
6. Harmonising Outcome Measures. [http://www.homeforeczema.org/]
7. Core Outcome Measures in Effectiveness Trials Initiative. [http://www.comet-initiative.org/]
8. Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, Kantor J, Kim E, Militello G, McGinnis K, Richardson S, Treat J, Vittorio C, Van Voorhees A, Werth VP: The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005, 125:889-94.
9. Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, Caux F, Marinovic B, Sinha AA, Hertl M, Bernard P, Sirois D, Cianchini G, Fairley JA, Jonkman MF, Pandya AG, Rubenstein D, Zillikens D, Payne AS, Woodley D, Zambruno G, Aoki V, Pincelli C, Diaz L, Hall RP, Meurer M, Mascaro JM, Schmidt E, Shimizu H, Zone J, et al.: Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol 2012, 66:479-85.
10. Singer AJ, Thode HC, Hollander JE: Research fundamentals: selection and development of clinical outcome measures. Acad Emerg Med 2000, 7:397-401. (Pubitemid 30207983)
11. Bonilla-Martinez ZL, Albrecht J, Troxel AB, Taylor L, Okawa J, Dulay S, Werth VP: The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol 2008, 144:173-80. (Pubitemid 351287000)
12. Klein R, Moghadam-Kia S, Lo Monico J, Okawa J, Coley C, Taylor L, Troxel AB, Werth VP: Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol 2011, 147:203-8.
13. Klein RQ, Bangert CA, Costner M, Connolly MK, Tanikawa A, Okawa J, Rose M, Fakharzadeh SS, Fiorentino D, Lee LA, Sontheimer RD, Taylor L, Troxel AB, Werth VP: Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008, 159:887-94.
14. Yassaee M, Fiorentino D, Okawa J, Taylor L, Coley C, Troxel AB, Werth VP: Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. Br J Dermatol 2010, 162:669-73.
15. Goreshi R, Okawa J, Rose M, Feng R, Lee LA, Hansen CB, Bangert CA, Connolly MK, Davis MD, Callen JP, Fett NM, Fakharzadeh SS, Clarke JT, Werth VP: Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. J Invest Dermatol 2012, 132:1117-24.
16. Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, Miller FW: Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken) 2011, 63(Suppl 11):S118-57.
17. Rosenbach M, Murrell DF, Bystryn J, Dulay S, Dick S, Fakharzadeh S, Hall R, Korman NJ, Lin J, Okawa J, Pandya AG, Payne AS, Rose M, Rubenstein D, Woodley D, Vittorio C, Werth BB, Williams EA, Taylor L, Troxel AB, Werth VP: Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol 2009, 129:2404-10.
18. Daniel BS, Hertl M, Werth VP, Eming R, Murrell DF: Severity score indexes for blistering diseases. Clin Dermatol 2012, 30:108-13.
19. Arkachaisri T, Vilaiyuk S, Torok KS, Medsger TA: Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. Rheumatology (Oxford) 2010, 49:373-81.
20. Fett N, Werth VP: Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol 2011, 64:231-42; quiz 243-4.
21. Krathen MS, Dunham J, Gaines E, Junkins-Hopkins J, Kim E, Kolasinski SL, Kovarik C, Kwan-Morley J, Okawa J, Propert K, Rogers N, Rose M, Thomas P, Troxel AB, Van Voorhees A, Feldt JV, Weber AL, Werth VP: The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology. Arthritis Rheum 2008, 59:338-44. (Pubitemid 351399203)
22. Kreuter A, Tomi NS, Weiner SM, Huger M, Altmeyer P, Gambichler T: Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol 2007, 156:1321-7. (Pubitemid 47029802)
23. Erceg A, Bovenschen HJ, Van De Kerkhof P C M, De Jong E M J G, Seyger M M B: Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus. J Am Acad Dermatol 2009, 60:626-32.
24. Kreuter A, Gaifullina R, Tigges C, Kirschke J, Altmeyer P, Gambichler T: Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Arch Dermatol 2009, 145:244-8.
25. Shah A, Albrecht J, Bonilla-Martinez Z, Okawa J, Rose M, Rosenbach M, Werth VP: Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol 2009, 145:303-6.
26. Chang AY, Piette EW, Foering KP, Tenhave TR, Okawa J, Werth VP: Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol 2011, 147:1261-7.
27. Braunstein I, Goodman NG, Rosenbach M, Okawa J, Shah A, Krathen M, Kovarik CL, Luning Prak E, Werth VP: Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. J Am Acad Dermatol 2012, 66:571-82.
28. Cortés-Hernàndez J, Torres-Salido M, Castro-Marrero J, Vilardell-Tarres M, Ordi-Ros J: Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol 2012, 166:616-23.
29. Cortés-Hernàndez J, Avila G, Vilardell-Tarrés M, Ordi-Ros J: Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther 2012, 14:R265.
30. Klein R, Moghadam-Kia S, Taylor L, Coley C, Okawa J, Lo Monico J, Chren M, Werth VP: Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol 2011, 64:849-58.
31. Goreshi R, Chock M, Foering K, Feng R, Okawa J, Rose M, Fiorentino D, Werth V: Quality of life in dermatomyositis. J Am Acad Dermatol 2011, 65:1107-16.
32. Vasquez R, Wang D, Tran QP, Adams-Huet B, Chren M, Costner MI, Cohen JB, Werth VP, Chong BF: A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus. Br J Dermatol 2013, 168:145-53.
33. Chang AY, Ghazi E, Okawa J, Werth VP: Quality of life differences between responders and nonresponders in the treatment of cutaneous lupus erythematosus. JAMA Dermatol 2013, 149:104-6.
34. Finlay AY: Measurement of disease activity and outcome in atopic dermatitis. Br J Dermatol 1996, 135:509-15. (Pubitemid 26340258)
35. Fabbrocini G, Panariello L, De Vita V, Vincenzi C, Lauro C, Nappo D, Ayala F, Tosti A: Quality of life in alopecia areata: a diseasespecific questionnaire. J Eur Acad Dermatol Venereol 2012.
36. Braunstein I, Klein R, Okawa J, Werth VP: The interferonregulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. Br J Dermatol 2012, 166:971-5.
37. Oh SH, Roh HJ, Kwon JE, Lee SH, Kim JY, Choi HJ, Lim BJ: Expression of interleukin-17 is correlated with interferon-a expression in cutaneous lesions of lupus erythematosus. Clin Exp Dermatol 2011, 36:512-20.
38. Nabatian AS, Bashir MM, Wysocka M, Sharma M, Werth VP: Tumor necrosis factor α release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients. Arthritis Res Ther 2012, 14: RI.
39. Rahman P, Gladman DD, Urowitz MB: Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol 1998, 25:1716-9. (Pubitemid 28439264)
40. Dutz J, Werth VP: Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma. J Invest Dermatol 2011, 131:1968-70.
41. Robinson A, Kardos M, Kimball AB: Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol 2012, 66:369-75.
42. Fernandez-Peñas P, Jones-Caballero M, Espallardo O, García-Díez A: Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis. Br J Dermatol 2012, 166:884-7.
43. Chang C: The limitations in defining clinically meaningful improvement in disease activity in patients with mild CLE [abstract]. J Invest Dermatol 2013.
44. Inzinger M, Weger W, Heschl B, Salmhofer W, Quehenberger F, Wolf P: Methotrexate vs. fumaric acid esters in moderate-tosevere chronic plaque psoriasis: data registry report on the efficacy under daily life conditions. J Eur Acad Dermatol Venereol 2012.
45. Papp KA, Reid C, Foley P, Sinclair R, Salinger DH, Williams G, Dong H, Krueger JG, Russell CB, Martin DA: Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol 2012, 132:2466-9.
46. Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R: Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006, 10:1-233, i-iv.
47. Faust HB, Gonin R, Chuang TY, Lewis CW, Melfi CA, Farmer ER: Reliability testing of the dermatology index of disease severity (DIDS). An index for staging the severity of cutaneous inflammatory disease. Arch Dermatol 1997, 133:1443-8. (Pubitemid 27490570)
48. Williams HC: Is a simple generic index of dermatologic disease severity an attainable goal? Arch Dermatol 1997, 133:1451-2. (Pubitemid 27490571)
49. Stamatas GN, Zmudzka BZ, Kollias N, Beer JZ: In vivo measurement of skin erythema and pigmentation: new means of implementation of diffuse reflectance spectroscopy with a commercial instrument. Br J Dermatol 2008, 159:683-90.
50. Syed ZU, Hamzavi IH: Photomedicine and phototherapy considerations for patients with skin of color. Photodermatol Photoimmunol Photomed 2011, 27:10-6.
51. Lahti A, Kopola H, Harila A, Myllylä R, Hannuksela M: Assessment of skin erythema by eye, laser Doppler flowmeter, spectroradiometer, two-channel erythema meter and Minolta chroma meter. Arch Dermatol Res 1993, 285:278-82. (Pubitemid 23256004)
52. Quinn AG, McLelland J, Essex T, Farr PM: Quantification of contact allergic inflammation: a comparison of existing methods with a scanning laser Doppler velocimeter. Acta Derm Venereol 1993, 73:21-5. (Pubitemid 23071339)
53. Ormerod AD, Dwyer CM, Weller R, Cox DH, Price R: A comparison of subjective and objective measures of reduction of psoriasis with the use of ultrasound, reflectance colorimetry, computerized video image analysis, and nitric oxide production. J Am Acad Dermatol 1997, 37:51-7. (Pubitemid 27287693)
54. Yokogawa N, Kato Y, Sugii S, Inada S: Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI). Mod Rheumatol 2012, 22:249-55.